Related Experiment Videos
[Combined effect of S-1 and CDDP as a modulator for colon 26 liver metastasis]
M Kitamura1, K Arai, Y Iwasaki
1Dept. of Surgery, Tokyo Metropolitan Bokutoh Hospital.
Abstract:
S-1 is a novel oral anticancer drug, composed of tegafur (FT), gimestat (CDHP) and otastat potassium (Oxo) in a molar ratio of 1:0.4:1, based on the biochemical modulation of 5-fluorouracil (5-FU). In this study the combined effect of S-1 and low-dose CDDP as a modulator for colon 26 liver metastasis in mice was evaluated. In an experiment with S-1 (5 mg/kg/day: po) and CDDP (0.25 mg/kg/day: i.p.) for 14 days, the combined effects for both liver metastasis and tumor of spleen were not superior to those with S-1 or CDDP alone group. Body weight loss was not greater in the S-1 + CDDP group than in the control group. In an experiment with S-1 (5 mg x 2/kg/day: po) and CDDP (0.25 mg/kg/day: i.p.) for 7 days, the inhibitory effects of S-1 + CDDP of liver metastasis and tumor of the spleen were remarkable compared with the S-1 alone group. However a greater loss of body weight was seen in the S-1 + CDDP group than in other groups. This study suggests that low-dose CDDP might be a modulator of S-1 for colon 26 liver metastasis. Further study is needed to determine the optimum dose and duration of treatment.
Insights
This study investigated S-1 combined with low-dose cisplatin (CDDP) for colon 26 liver metastasis in mice. While not superior in initial tests, a modified regimen showed remarkable tumor inhibition, suggesting CDDP may modulate S-1 efficacy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Metastasis Research
Background:
- S-1 is an oral anticancer drug modulating 5-fluorouracil (5-FU).
- Cisplatin (CDDP) is a chemotherapy agent.
- Colon 26 liver metastasis in mice is a model for cancer spread.
Purpose of the Study:
- To evaluate the combined effect of S-1 and low-dose CDDP on colon 26 liver metastasis.
- To assess S-1 and CDDP as potential modulators for cancer treatment.
Main Methods:
- Mice with colon 26 liver metastasis were treated with S-1 and low-dose CDDP.
- Two experimental regimens with different dosing schedules were used.
- Tumor burden, liver metastasis, spleen tumor, and body weight were monitored.
Main Results:
- A 14-day treatment with S-1 (5 mg/kg/day) and CDDP (0.25 mg/kg/day) showed no superior effect over monotherapy.
- A 7-day treatment with S-1 (5 mg x 2/kg/day) and CDDP (0.25 mg/kg/day) demonstrated remarkable inhibition of liver metastasis and spleen tumor.
- The enhanced efficacy group experienced greater body weight loss.
Conclusions:
- Low-dose CDDP may act as a modulator for S-1 in treating colon 26 liver metastasis.
- Further research is required to optimize the dosage and duration of combined S-1 and CDDP therapy.
- This combination therapy shows potential for managing liver metastasis and spleen tumors.